New hormone shot could free patients from daily calcium pills
NCT ID NCT04701203
First seen Feb 15, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This phase 3 trial tested a daily injection called TransCon PTH in 84 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone. For 26 weeks, some participants received the drug and others a placebo, without knowing which. The goal was to see if the drug could bring calcium levels back to normal and reduce the need for high-dose calcium and vitamin D supplements. After the blinded period, everyone could receive the drug long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ascendis Pharma Investigational Site
San Francisco, California, 94143, United States
-
Ascendis Pharma Investigational Site
Chicago, Illinois, 60637, United States
-
Ascendis Pharma Investigational Site
Rochester, Minnesota, 55905, United States
-
Ascendis Pharma Investigational Site
Reno, Nevada, 89511, United States
-
Ascendis Pharma Investigational Site
New York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
Greenville, North Carolina, 27834, United States
-
Ascendis Pharma Investigational Site
Austin, Texas, 78731, United States
-
Ascendis Pharma Investigational Site
Fort Worth, Texas, 76132, United States
-
Ascendis Pharma Investigational Site
Spokane, Washington, 99204, United States
-
Ascendis Pharma Investigational Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Ascendis Pharma Investigational Site
Oakville, Ontario, L6M 1M1, Canada
-
Ascendis Pharma Investigational Site
Québec, Quebec, G1V 4G2, Canada
-
Ascendis Pharma Investigational Site
Copenhagen, Capital Region, 2100, Denmark
-
Ascendis Pharma Investigational Site
Aarhus, Central Jutland, 8200, Denmark
-
Ascendis Pharma Investigational Site
Dresden, Saxony, 01307, Germany
-
Ascendis Pharma Investigational Site
Szeged, Csongrád megye, 6720, Hungary
-
Ascendis Pharma Investigational Site
Budapest, 1083, Hungary
-
Ascendis Pharma Investigational Site
Bologna, Emilia-Romagna, 40138, Italy
-
Ascendis Pharma Investigational Site
Rome, Lazio, 00128, Italy
-
Ascendis Pharma Investigational Site
Pisa, Piacenza, 56126, Italy
-
Ascendis Pharma Investigational Site
Oslo, 0176, Norway
Conditions
Explore the condition pages connected to this study.